Expert Opinion on Drug Metabolism & Toxicology

Papers
(The H4-Index of Expert Opinion on Drug Metabolism & Toxicology is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Probing the mechanism of reduced in vivo potency of insulin detemir130
Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata92
A three-arm clinical study to compare pharmacokinetic and pharmacodynamic similarity of the denosumab biosimilar LY06006 with reference denosumab in healthy male subjects47
Comorbidities and the right dose: antipsychotics47
A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database38
Pharmacotherapy in kidney disease: what it takes to move from general guidance to specific recommendations to stratified subgroups of patients - the tale of autosomal dominant polycystic kidney diseas36
Drug metabolizing enzymes and transporters, and their roles for the development of drug-induced liver injury35
An update on pharmacogenetic factors influencing the metabolism and toxicity of artemisinin-based combination therapy in the treatment of malaria31
Azole antifungals and inter-individual differences in drug metabolism: the role of pharmacogenomics and precision medicine24
The Central Role of Cytochrome P450 Reductase (CPR) in Hyperoxic Lung Injury24
Hormones, microbes, and PrEP drugs in the female genital tract23
Pharmacokinetics of S1P receptor modulators in the treatment of ulcerative colitis22
Guidance for interactions between antiseizure medications21
Immune-mediated liver injury caused by immune checkpoint inhibitors exhibits distinct clinical features that differ from autoimmune hepatitis20
The impact of genomic variants on patient response to inhaled bronchodilators: a comprehensive update20
Bioactivity descriptors for in vivo toxicity prediction: now and the future19
The safety and toxicity profile of SPL84, an inhaled antisense oligonucleotide for treatment of cystic fibrosis patients with the 3849 +10kb C->T mutation, supports a Phase 1/2 clinical study19
Pharmacokinetics and pharmacodynamics of approved monoclonal antibody therapy for colorectal cancer17
Current status and future perspectives on the use of therapeutic drug monitoring of thiopurine metabolites in patients with inflammatory bowel disease17
Pharmacokinetic, toxicological, and clinical considerations for the treatment of type 2 diabetes in patients with liver disease: a comprehensive update17
0.10093379020691